Proteomic and transcriptomic analyses identify apo-transcobalamin-II as a biomarker of overall survival in osteosarcoma
Overall, APO-TCN2, a circulatory protein previously described in various lymphoproliferative disorders, was associated with 2-year survival status in patients diagnosed with OSA. The relevance of this protein and apparent immunological function (anti-tumor B lymphocyte responses) was suggested using publicly available solid tumor RNA-sequencing datasets. Further studies characterizing the biological function of APO-TCN2 and its relevance in these diseases is warranted.
Authors
- Sebastian A. Dziadowicz (ORCID: https://orcid.org/0000-0001-6277-9310)
- Li Ma (ORCID: https://orcid.org/0000-0003-3212-0704)
- Ines Lohse (ORCID: https://orcid.org/0000-0002-9979-9400)
- Nicolás J. Llosa
- Karen Elizabeth Schoedel (ORCID: https://orcid.org/0000-0001-5398-8962)
- Kurt Richard Weiss (ORCID: https://orcid.org/0000-0003-3859-728X)
- Brock A. Lindsey (ORCID: https://orcid.org/0000-0002-1073-5372)
- Tanya E. Heim (ORCID: https://orcid.org/0000-0002-5808-6770)
- Brody Fitzpatrick
- Gangqing Hu (ORCID: https://orcid.org/0000-0001-5453-6888)
- Ryan A. Lacinski (ORCID: https://orcid.org/0000-0002-3026-2592)
- Clark Roth
- Vincent K. Melemai
- Edwin O. Chaharbakhshi
Institutions
- West Virginia University (US)
- Johns Hopkins University (US)
- University of Pittsburgh (US)
- Johns Hopkins Medicine (US)
- University of Pittsburgh Medical Center (US)
Publication Details
- Journal
- Frontiers in Oncology
- Published
- 2024-10-18
- DOI
- https://doi.org/10.3389/fonc.2024.1417459
- Citations
- 1
- Primary Topic
- Electrospun Nanofibers in Biomedical Applications
- Type
- article
- Field-Weighted Citation Impact
- 0.17